Overview
TQ Therapeutics develops innovative technologies for cell and gene therapy manufacturing, including the EXiVO extracorporeal approach for ultra-fast, automated processing of autologous T cells using mRNA-LNP. Their platform enables bedside delivery of personalized therapies in under five hours by integrating blood collection, cell isolation, genetic modification, and reinfusion. They license proprietary affinity-based cell selection technology to partners like Fresenius Kabi for scalable T-cell isolation from whole blood.
Frequently asked questions
- What is TQ Therapeutics' core technology for cell therapy?
- TQ Therapeutics' EXiVO platform uses extracorporeal in-vivo gene therapy, enabling automated, bedside processing of T cells from whole blood with transient mRNA-LNP modification in under five hours.
- What partnerships does TQ Therapeutics have for manufacturing?
- Fresenius Kabi has an exclusive license to TQ's affinity- and column-based T-cell isolation technology, integrating it into the Cue Cell Processing System for scalable cell therapy production.
- What therapeutic applications does TQ Therapeutics target?
- The company focuses on autologous mRNA-T-cell therapies for various indications, aiming to deliver personalized immunotherapies like CAR-T directly at the bedside.